arrow
T

Tito R. Mendoza

university of texas system
H指数:72
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CERN 09-02: A PHASE 2 TRIAL OF CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT ADULT EPENDYMOMA

CERN 09-02:一项关于卡铂和贝伐珠单抗治疗复发性成人室管膜瘤的II期临床试验

2025-11-010
OAAI
Psychometric Properties and Interpretability of PRO-CTCAE® Average Composite Scores as a Summary Metric of Symptomatic Adverse Event Burden

心理测量属性与PRO-CTCAE®平均综合分数作为症状性不良事件负担汇总指标的可解释性

2025-10-290
OAAI
Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report

神经肿瘤学反应评估(RANO)2009–2025:广泛范围与实施——进展报告

2025-06-012
PRE
Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative

基于WHO ICF框架建立神经肿瘤学中使用的患者报告结局指标的内容效度:RANO-PRO计划的一部分

2025-06-010
PRE
Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review

成人肿瘤学试验中新型疗法症状性毒性的患病率:一项范围综述

2025-03-270
OA
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)
2024-11-060
OAAI
Testing neuro-oncology tenets: are MRI findings and symptoms different with true progression compared with immunotherapy-related treatment effect in patients with primary brain tumors?
2024-03-040
PRE
Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors
2023-12-010
PRE